LB Pharmaceuticals公布LB-102治疗精神分裂症二期NOVA-1试验结果获《JAMA Psychiatry》刊载

美股速递
Apr 23

LB Pharmaceuticals公司宣布,其针对精神分裂症治疗的创新药物LB-102二期临床试验NOVA-1的研究成果,已正式发表于国际权威期刊《美国医学会精神病学杂志》(JAMA Psychiatry)。该论文的刊登标志着该药物临床数据获得学界认可,为后续研发提供重要学术支撑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10